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Poster Session I 83days post SCT. In summary, NAC and AlloSCT in patients with
SCD using both related and unrelated donors has been shown to
be well tolerated and effective in inducing a high degree of mixed
donor chimerism.222
DONOR CHIMERISM KINETICS IN PEDIATRIC PATIENTS UNDERGOING
REDUCED INTENSITY CONDITIONING (RIC) WITH ALLOGENEIC HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
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Jacobsohn, D.A.1, Duerst, R.1, Kletzel, M.1. 1Children’s Memorial Hos-
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From 9/03–9/07 fifty-three children with malignant (n5 31) and
non-malignant diseases (immune deficiencies, metabolic disorders,
severe aplastic anemia, n5 22) underwent RIC HSCT; median age
at time of HSCT was 8 years (1 month - 17 years). RIC included flu-
darabine 30 mg/m2/d  5 d and targeted (AUC 4000 micorMol*-
min) single daily IV busulfanX2d (n 5 4), 1 ATG(n 5 34) or 2
weekly treatments of extracorporeal photopheresis (ECP, n 5 12).
Three received other fludarabine-based regimens. GVHD prophy-
laxis included CSA6MMF (n5 53),1 post-HSCT ECP (n5 12).
Neutrophil and platelet recovery were defined as 1st of three con-
secutive ANC . 500/ml and platelet count . 20,000/ml without
transfusion. Lineage specific chimerism assays of total white
cells(TW), T-cell (CD3), and myeloid cells (CD33) were moni-
tored serially post-HSCT by variable number tandem re-
peats(VNTR) assays. Full donor chimerism (FDC) was defined
as$95 1 5%, subsequent loss of full donor chimerism was defined
as a drop below 50%. Patients who did not reach 95% were termed
mixed chimerism. Neutrophil recovery occured in 94% at a median
of 18 days (4–39); one never fell below 500/ml. Platelet recovery was
evaluated in 52; 54% did not fall below 20,000/ l, 40% reached
20,000/ml (median 20 days, 9 – 158), and 38% reached 50,000/ml
(median 20.5 days, 11–142). Median cell doses per kilogram body
weight were as follows: CD34 6.77  106 (0.12 – 25.8), MNC
4.84 108 (0.27 – 8.85), and TNC 8.15 108 (0.41 – 46.1). No cor-
relation between cell dose and neutrophil recovery was seen; signif-
icant correlation was seen between cell dose and platelet recovery
(CD34, p 5 0.009, MNC, p 5 0.05, TNC, p 5 0.02). Patients
who received RIC HSCT (Table 1) for malignant disorders when
compared with non-malignant disorders showed a significant differ-
ence in achieving FDC in TW (p 5 0.0002) and myeloid (p 5
0.0002) cell lines. Two lost TW chimerism (malignant n 5 1, day
46, non-malignant n 5 1, day 340). 17/53 achieved mixed chime-
rism (malignant n 5 4, non-malignant n 5 13); those with malig-
nant disease received second HSCT. Non-malignant patients
remain free of disease (2nd HSCT n 5 7). There is significant dif-
ference in achieving FDC in those pts with malignancies which may
be attributed to prior therapy. Stable partial chimerism may be suf-
ficient in pts with non-malignant diseases. Chimerism requires fre-
quent monitoring; interventions such as changing immune
suppression or donor lymphocyte infusions must be considered.Table 1.
Median MedianRIC With
Allo-HSCTFDC
TW (%)Median
Time to FDC
TW (days)FDC
T-cell (%)Time to
FDC T-cell
(days)FDC
Myeloid
Cell (%)Time to
FDC Myeloid
(days)All Patients
(n 5 53)68% 48 69% 99 75% 29Malignant
Diseases
(n 5 31)87% 33 82% 97 85% 26Non-Malignant
Diseases
(n 5 22)41% 383 52% 169 48% 167p 5 0.0002 p 5 0.1 p 5 0.0002223
ALTERNATIVE DONOR HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION FOR PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKE-
MIA USING CAMPATH IN A MYELOABLATIVE CONDITIONING REGIMEN
Kennedy-Nasser, A.A., Myers, G.D., Leung, K.S., Gottschalk, S.,
Bollard, C.M., Heslop, H.E., Brenner,M.K., Krance, R.A. Baylor College
ofMedicine, Texas Children’s Hospital, TheMethodist Hospital, Houston,
TX.
Allogeneic transplantation from a matched sibling donor (MSD)
offers curative therapy for pediatric patients with acute lymphoblas-
tic leukemia (ALL); however, less than 30% of patients will have
a MSD. Alternative donor (AD) transplantation is a viable option
for these patients, but the risk for GVHD remains much higher.
From 2001 to present, we have used Campath in the conditioning
regimen for AD transplants to achieve in vivo T-cell depletion, in
an effort to reduce the risk of GVHD. Here we report the outcome
of pediatric ALL patients receiving AD transplants using Campath
as part of a myeloablative conditioning regimen. Risk assessment is
assigned prior to transplant – standard risk (SR) includes patients
with ALL in 1st or 2nd complete remission. Since 1997, 39 patients
with SR ALL were transplanted with MSD grafts, and since institut-
ing Campath in 2001, 39 patients have received AD grafts. AD pa-
tients received bone marrow or peripheral blood stem cell products
from up to 1 antigen mismatched related or unrelated donor. Mye-
loablative conditioning included cyclophosphamide, cytarabine
arabinoside and total body irradiation (1200 cGy for MSD and
1400 cGy for AD) in all patients with the addition of Campath in
the AD recipients. Additional GVHD prophylaxis consisted of
FK506 or cyclosporine with either methotrexate or prednisone.
All but one evaluable patient achieved neutrophil engraftment.
The 5-year disease-free survival for patients with MSD was 83%
compared to 60% for AD recipients. The 100-day mortality was
8% in the AD group and 3% in the MSD group. GVHD was low
in the AD cohort – 13% developed grade II-IV acute GVHD and
none developed extensive, chronic GVHD. Consistent with other
published reports using Campath, we did observe a high incidence
of viral infections – 28% developed adenovirus reactivation; 28%
developed CMV reactivation; and 3% developed EBV-LPD. We
conclude that Campath used with a myeloablative conditioning reg-
imen offers a curative option for pediatric patients with acute lym-
phoblastic leukemia requiring alternative donor transplantation
with a low incidence of GVHD.224
OUTCOMES OF UNRELATED UMBILICAL CORD BLOOD TRANSPLANTA-
TION IN PEDIATRIC PATIENTS WITH MYELODYSPLASTIC SYNDROME
Parikh, S.H.1, Mendizabal, A.2, Martin, P.L.1, Szabolcs, P.1,
Prasad, V.K.1, Driscoll, T.A.1, Kurtzberg, J.1. 1Duke UniversityMedical
Center, Durham, NC; 2The EMMES Corporation, Rockville, MD.
Between 1995 and 2007, 24 pediatric patients were transplanted
with unrelated donor umbilical cord blood (UCB). M:F ratio was
1.4; the median age was 10.5 years (range 1.11–19.73). Median
time from diagnosis to transplant was 6.43 months (range 2.00–
61.37). Patients were followed for a median time of 5.68 years (range
0.45–11.57). Eighty percent had primary disease. MDS stage was
RA/RC 12 pts, RAEB 8 pts and RAEB-T 4 pts. Monosomy-7 was
present in 18 (75%) patients. Patients with frank AML were ex-
cluded. Preparative regimen was TBI based in 19 (79%) patients
while Melphalan was used in 14 (58%) patients. GVHD prophylaxis
consisted of CSA/steroids (19 pts) and CSA/mycophenolate (5 pts).
Grafts were selected for matching at HLA Class I (A and B) at low
resolution and HLA Class II (DRB1) at the allelic level resulting in
17 (71%) 4/6 and 7 (29%) 5/6 matched transplants. The grafts con-
tained a median of 4.22  107 (range 1.68–12.58) total nucleated
cells (TNC)/kg pre-cryopreservation; 3.58  107 (range 1.01–
12.00) TNC/kg and 1.71 105/kg (range 0.17–28.46) CD341 cells
were infused. Cumulative incidence of neutrophil engraftment
(ANC . 500/mL) at Day 42 and Day 100 was 70.8% (95% CI
51.8%-89.8%) and 92.7% (95% CI 75.5%-100.0%), respectively,
and that of platelet engraftment (50K) at 180 days was 66.7%
(46.9%-86.5%). Three pts had graft failure while 4 pts (16%)
